Oncoral phase 1 results to be presented at ESMO congress in Munich
Ascelia Pharma announces today that results of the Phase I study for Oncoral has been accepted as a poster presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Munich, Germany, 19-23 October 2018.About the Phase I study: Oncoral has been evaluated in an investigator sponsored Phase I trial at the Department of Oncology at Herlev Hospital in Denmark. The study was a dose-escalating safety, tolerability and pharmacokinetics study of orally administered Oncoral in adult patients with advanced solid tumours. The objectives of the study were to determine the